Inspire Pharmaceuticals — Corporate Update (January 2009)
11 slides from Inspire Pharmaceuticals's corporate update, Jan 27, 2009
Slide 1: Prolacria Program Background Information
Inspire Pharmaceuticals Prolacria™ Program Background Information January 27, 2009
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995, which convey management's expectations, beliefs, plans and objectives regarding future performance. These statements discuss matters that are not facts
Slide 3: Dry Eye Disease
Dry Eye Disease Disorder of the tear film that causes damage to the ocular surface and symptoms of ocular discomfort and fluctuating vision Heterogeneous disease characterized by reduced tear production, defective tear film composition and/or evaporative loss of fluid Causes damage to the ocular sur
Slide 4: Diquafosol Tetrasodium: Novel Molecule
Diquafosol Tetrasodium: NovelMolecule Discovered byInspireforDryEye O O HN HN O N O N O O O O O P O P O P O P O O - - - - O O O O O OH OH 4 Na + OH OH P1,P4-di (uridine 5’-) tetraphosphate, tetrasodium salt Potent and selective agonist 2atreceptor P2Y on corneal and conjunctival epithelial surfaces
Slide 5: Prolacria Phase 3 Environmental Clinical Testing
TM Prolacria Phase3 Environmental ClinicalTesting Study Clinical Size Duration Primary Efficacy Endpoint Phase (ITT) 03-104 3 544 12 weeks + 40 Reduction in mean corneal staining & weeks for safety worst symptom score Environmental 03-105 3 519 24 weeks Reduction in mean corneal staining & Environme
Slide 6: Improvements in Mean Central Corneal Staining
Improvements In Mean Central Corneal Staining Reduction of mean central corneal staining scores in Phase 3 environmental trials for all patients, regardless of baseline staining (Intent-to-Treat Population) 03-104 03-105 03-109 Placebo Prolacria Placebo Prolacria Placebo Prolacria p-value p-value p-
Slide 7: Clearing of Central Corneal Staining
Clearing of Central Corneal Staining Proportion of all patients, regardless of baseline staining, that achieved clearing of central corneal staining (NEI score of 0) at Week 6 Endpoint in the Phase 3 environmental trials (Intent-to-Treat Population) 03-104 03-105 03-109 Placebo Prolacria Placebo Pro
Slide 8: Clearing of Central Corneal Staining in Patients With Baseline Scores of 2 or 3
Clearing of Central Corneal Staining in Patients With Baseline Central Corneal Staining Scores of 2 or 3 Proportion of patients with a baseline NEI staining score of 2 or 3 in the central cornea thatachievedclearingofcentralcornealstaining(NEIscoreof0)atWeek6 Endpoint in the Phase 3 environmental tr
Slide 9: Clearing of Central Corneal Staining in Patients With Baseline Score of 3
Clearing of Central Corneal Staining in Patients With Baseline Central Corneal Staining Score of 3 Proportion of patients with a baseline NEI staining score of 3 in the central cornea that achieved clearing of central corneal staining (NEI staining score of 0) at Week 6 Endpoint in the Phase 3 envir
Slide 10: Recent Regulatory History
Recent Regulatory History TM OriginalNDAforProlacria submitted June2003aftertwoPhase3 clinical trials (03-104 and 03-105) Approvable Letter received from FDA in Dec 2003 NDA amendment filed June 2005 (with results from two additional clinical trials03-108 – and 03-109) Second Approvable Letter recei
Slide 11: Prolacria Phase 3 Environmental Clinical Trial (03-113)
TM Prolacria Phase 3 Environmental Clinical Trial (03-113) R Primary Endpoint: A Prolacria • Proportion of subjects N = 450 N (diquafosol tetrasodium receiving Prolacria that Inclusion Criteria: ophthalmic solution 2%) achieve clearing of • Corneal fluorescein staining D QID fluorescein staining of
Inspire Pharmaceuticals — Corporate Update (January 2009) on 6ix